Drug intelligence / Profile preview

RI-OR2

Development stage: Preclinical
Lead developer: Lancaster University
Modality: Peptides
Administration: Peripheral Injection

Overview

RI-OR2 is a proteolytically stable retro-inverso peptide inhibitor designed to target the aggregation of amyloid-beta (Abeta) in Alzheimer's disease. It is a D-amino acid analogue of the peptide OR2 (RGKLVFFGR), specifically engineered to resist degradation by proteases in human plasma and brain extracts. RI-OR2 functions by binding to Abeta monomers and fibrils, thereby blocking the formation of toxic soluble Abeta oligomers and inhibiting fibril extension. Developed by researchers at Lancaster University, the peptide has demonstrated the ability to reverse Abeta-induced neurotoxicity in SH-SY5Y neuroblastoma cells, making it a candidate for the treatment of the underlying causes of Alzheimer's disease.

Other names: retro-inverso OR2rGklvffGr

Targets

Aβ42 aggregate (Amyloid-β 42 aggregate)

Beyond the preview

Go deeper on RI-OR2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RI-OR2.

Explore the full profile